Quibim Raises $50 Million Series A: pioneering the future of medical imaging with AI

At Kfund, we are proud to celebrate a major milestone for our portfolio company Quibim. Today, the company announced the successful close of its $50 million Series A financing round, a significant step in its journey to transform medical processes through AI-powered imaging. We are grateful to be part of Ángel Alberich-Bayarri and his team’s journey toward innovation and impact.

The round was led by Asabys Partners (via its Sabadell Asabys II fund) and joined by Buenavista Partners, UI Investissements, and Go Hub as new investors. Returning investors included Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, and prominent individual investors like Tony Fadell, inventor of the iPod and founder of Nest, and Dr. Jonathan Milner, founder of Abcam plc.

Quibim specializes in developing foundational AI models for imaging that derive actionable insights from MRI, CT, and PET scans. These tools are instrumental in the early detection and monitoring of complex diseases, including cancer, Alzheimer’s, and liver disorders. Additionally, Quibim’s solutions empower pharmaceutical companies by enhancing precision clinical trials and enabling predictive treatment planning, improving outcomes for patients worldwide.

Leveraging New Funding for Global Expansion

The Series A funding will fuel Quibim’s expansion into the U.S. market, where it aims to deepen partnerships with pharmaceutical leaders. The funds will also enable the launch of new medical imaging products and further integrate AI-powered tools into clinical workflows, driving the adoption of precision medicine globally.

Quibim stands out in the competitive medtech space for several reasons:

• Radiologists and other healthcare professionals face increasing workloads and complexity. Quibim’s technology acts as a powerful enabler, automating detailed image analysis and comparison to reduce workloads and improve diagnostic efficiency.
• Quibim has built strong alliances with global medical equipment leaders like Philips, as well as leading radiologists, hospitals, and pharma companies in Europe and the U.S., such as Merck KGaA, cementing its reputation as a trusted and high-quality innovator in medical imaging.
• Through its non-invasive virtual biopsy diagnostics, Quibim offers faster, safer, and more precise alternatives to traditional biopsies, improving patient care and reducing risks.
• Founder Angel Alberich-Bayarri is a visionary in radiomics, aiming to redefine its role from merely detecting lesions to enabling prescriptive tools for complex diagnoses. His leadership is the driving force behind Quibim’s trailblazing advancements.
• Achieving CE and FDA clearances for its diagnostic tools validates Quibim’s commitment to innovation and has positioned the company as a leader in radiomics.

Redefining Radiomics

Quibim’s approach has the potential to revolutionize healthcare by making complex diagnoses simpler and less invasive. Much like Foundation Medicine reshaped genomics, Quibim aims to transform radiomics into a prescriptive, actionable tool that enables precise and personalized treatment plans.

As Quibim continues its journey, we are excited to stand by its side, supporting its mission to improve patient outcomes and redefine the future of medical imaging.

‍

‍